Skip to main content
. 2023 Sep 23;7(21):6762–6766. doi: 10.1182/bloodadvances.2023010742

Figure 1.

Figure 1.

Time to next treatment and survival analysis. (A) TTNT calculated on each treatment received (it includes also patients who received rituximab more than once). (B) Progression-free survival determined on 33 patients from the initiation of the (first) treatment with rituximab to the date of progression, death, or last follow-up. (C) Overall survival determined on 33 patients from the initiation of the (first) treatment with rituximab to the date of death or last follow-up.